AstraZeneca (AZ) and Daiichi Sankyo (DS) are pleased to announce that Canada's Drug Agency (CDA, formerly CADTH) has issued a Time-Limited Reimbursement (TLR) recommendation – the first in gastric ...

The trial’s primary endpoint is pCR, with secondary endpoints including event-free survival (EFS), overall survival, safety, and invasive disease-free survival.

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) ...

ZoomRx polled 50 experienced oncologists and hemato-oncologists about 20 cancer drugmakers, asking the doctors to rank the ...

ENHERTU is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo.

Enhertu is a specifically engineered HER2-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed and commercialised by AstraZeneca and Daiichi Sankyo.

In an AstraZeneca-developed training program, AI-assisted HER2 IHC scores had higher agreement with centrally confirmed scores.

2,3 Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: “The clinically meaningful improvement in pathologic complete response and the safety data seen in ...